HMOX1 and metabolic dysfunction-associated steatotic liver disease: It exhibits potential therapeutic effects on non-alcoholic fatty liver disease by promoting autophagy through the down-regulation of ubiquitin A-52 residue ribosomal protein fusion product 1, activating Nrf2/HO-1 to inhibit oxidative stress, and attenuate non-alcoholic fatty liver disease [109].